Werewolf Therapeutics Revenue vs. EBITDA
| HOWL Stock | USD 2.00 0.10 5.26% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 19.9 M | Current Value 20.9 M | Quarterly Volatility 7.9 M |
For Werewolf Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Werewolf Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Werewolf Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Werewolf Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Werewolf Therapeutics over time as well as its relative position and ranking within its peers.
Werewolf |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.082 | Quarterly Revenue Growth (0.86) | Return On Assets (0.26) | Return On Equity (0.62) |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Werewolf Therapeutics EBITDA vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Werewolf Therapeutics's current stock value. Our valuation model uses many indicators to compare Werewolf Therapeutics value to that of its competitors to determine the firm's financial worth. Werewolf Therapeutics is rated # 3 in revenue category among its peers. It is rated # 5 in ebitda category among its peers . At this time, Werewolf Therapeutics' Total Revenue is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Werewolf Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Werewolf Revenue vs. Competition
Werewolf Therapeutics is rated # 3 in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 116.83 Million. Werewolf Therapeutics retains roughly 19.94 Million in revenue claiming about 17% of equities under Health Care industry.
Werewolf EBITDA vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Werewolf Therapeutics |
| = | 19.94 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Werewolf Therapeutics |
| = | (32.47 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Werewolf EBITDA Comparison
Werewolf Therapeutics is currently under evaluation in ebitda category among its peers.
Werewolf Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Werewolf Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Werewolf Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Werewolf Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Werewolf Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -161.3 M | -169.4 M | |
| Net Interest Income | 4.5 M | 4.7 M | |
| Operating Income | -40.5 M | -42.5 M | |
| Net Loss | -37.3 M | -39.2 M | |
| Income Before Tax | -37.4 M | -39.2 M | |
| Total Other Income Expense Net | 3.1 M | 2.8 M | |
| Net Loss | -61.9 M | -58.8 M | |
| Net Loss | -37.4 M | -39.2 M | |
| Income Tax Expense | 1.6 M | 1.7 M | |
| Interest Income | 4.5 M | 4.7 M | |
| Non Operating Income Net Other | 2.6 M | 1.3 M | |
| Change To Netincome | 8.5 M | 8.9 M | |
| Net Loss | (1.05) | (1.10) | |
| Income Quality | 0.87 | 1.02 | |
| Net Income Per E B T | 0.96 | 1.10 |
Werewolf Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Werewolf Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Werewolf Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Werewolf Therapeutics' important profitability drivers and their relationship over time.
Use Werewolf Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Werewolf Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Werewolf Therapeutics will appreciate offsetting losses from the drop in the long position's value.Werewolf Therapeutics Pair Trading
Werewolf Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Werewolf Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Werewolf Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Werewolf Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Werewolf Therapeutics to buy it.
The correlation of Werewolf Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Werewolf Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Werewolf Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Werewolf Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Werewolf Therapeutics position
In addition to having Werewolf Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Wireless Thematic Idea Now
Wireless
Companies providing wireless technology and communication services. The Wireless theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wireless Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
To fully project Werewolf Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Werewolf Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Werewolf Therapeutics' income statement, its balance sheet, and the statement of cash flows.